Navigation Links
Valencell Secures Strategic Investment from Halma plc
Date:1/27/2020

Valencell, the leading innovator in wearable biometric sensor technology, today announced it has secured financing from strategic investors led by Halma plc, a FTSE 100 global group of life-saving technology companies, with additional participation from existing investors Sonion, TDF Ventures, GII LLC, and WSJ Joshua Fund. A representative from Halma will join the Valencell board of directors. Valencell plans to use the funds to accelerate investments in its biometric sensor systems, blood pressure technology, and sales growth.

In addition, Valencell announced the signing of a collaboration agreement with Halma plc portfolio company SunTech Medical Inc. Valencell and SunTech are cooperating on clinical-grade blood pressure solutions augmented with PPG sensor technology.

“Valencell has established a strong position in the convergence of consumer wearables and health & medical devices with advanced sensor technology to measure everything from heart rate to blood pressure,” said Kent Novak, CEO, Valencell. “With Halma leading the investment round, Valencell adds a new strategic partner with a large footprint in the health and medical sector, where Valencell is seeing great traction and opportunity. We look forward to working with our new and existing partners to expand Valencell core technology in the market.”

Valencell continues to see global demand for highly accurate biometric sensor technology with significant growth in hearables, hearing aids and other wearable devices. At CES 2020, Valencell recently launched the world’s first calibration-free blood pressure sensor system for hearables and wearables. Valencell’s technology has now been integrated into more than 50 different wearables and hearables that have come to market around the world. Valencell also has the most-cited patent portfolio in wearable PPG, which includes over 85 granted patents and more than 100 additional patents pending.

The market for wearable biometric sensors continues to rapidly expand largely driven by ear-based hearables. IDC recently said, “Hearables are the new wearables” and expects more than 273 million hearables to ship by 2023, showing 41.3% CAGR from 2019-2023. The wearables market as a whole is expected to ship nearly 500 million units by 2023.

About Valencell
Valencell transforms the science of wearable biometrics to enable impactful health outcomes. Through innovative R&D and validated technologies, we develop breakthroughs and collaborate with wearables, hearables, and medical device companies around the world to deliver amazing results. Protected by more than 85 granted patents and more than 100 patents pending, Valencell’s technology can be used in wearables and hearables for virtually anyone, anywhere, doing anything. Valencell’s biometric sensor systems are currently integrated into more wearable devices than any other technology provider in the world.

Read the full story at https://www.prweb.com/releases/valencell_secures_strategic_investment_from_halma_plc/prweb16863059.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related biology technology :

1. Valencell Files Patent Infringement Suit against Apple, Inc. and Fitbit, Inc.
2. MabPlex International Ltd. Secures $59.1 Million Series A Financing Round
3. Graphene Producer Grolltex Secures 'Seed B' Equity Financing Round
4. 3Bar Biologics Secures $2M To Help Farmers Increase Crop Yields with Naturally Occurring Microbes
5. DuPont Pioneer Secures Exclusive Rights to ERS Genomics’ CRISPR-Cas Patent Portfolio for Agriculture
6. Cybrexa Therapeutics Secures $6 Million in Series B Financing
7. Zansors Secures Issued Patent for Heart Monitoring Device
8. Dermata Therapeutics, LLC Closes a $5 Million Series 1a Financing and Secures a $5 Million Credit Facility with Silicon Valley Bank
9. Biocept Secures In-Network Provider Agreement with Blue Cross Blue Shield of Texas
10. Renova Therapeutics secures novel AAV vector license for use in metabolic and cardiovascular gene therapy development
11. Sorrento Therapeutics, Inc. Secures $75 Million Loan Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/14/2020)... LINDA, Calif. (PRWEB) , ... May 12, 2020 ... ... life science tools for translational research, is bringing together thousands of industry leaders, ... The scientific program highlights two plenary speakers, Carl June, MD, Director of the ...
(Date:5/5/2020)... ... 04, 2020 , ... Red Nucleus, a leading provider of ... that Informa Training Partners, a life sciences training company acquired by Red Nucleus ... immediately. , “The name change solidifies a stronger presence for Red Nucleus in ...
(Date:4/26/2020)... ... 23, 2020 , ... Indegene Omnipresence, Inc. announced the launch ... services for use on Microsoft Azure. The customer experience management (CXM) technology allows ... a built-for-purpose customer engagement capability to use in their commercial or medical operations. ...
(Date:4/22/2020)... ... April 21, 2020 , ... Ripple Science today announced new ... teams are working remotely and have paused patient visits, forcing teams to do ... research during this uncertain time by giving research teams free access to Ripple ...
Breaking Biology Technology:
(Date:5/14/2020)... ... May 12, 2020 , ... ... Science Manufacturers accurately and easily project contracted liabilities with payers, providers and ... by projecting discounts/rebates to Commercial and Government entities, Copay and Patient Assistance ...
(Date:5/11/2020)... ... May 11, 2020 , ... Octagos Health, ... patients with implanted cardiac devices. The Octagos software allows healthcare professionals access to ... greatly simplifies the management of remote transmissions and at the same time provides ...
(Date:5/1/2020)... , ... April 30, 2020 , ... ... backed by Siemens Healthineers and several healthcare VC firms announces an official launch ... of CareDoctors.com is to enhance patient care experience by offering live video consultations ...
Breaking Biology News(10 mins):